Key Insights
- Chongqing Genrix Biopharmaceutical’s significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public
- The largest shareholder of the company is Chongqing Zhirui Investment Co., Ltd. with a 55% stake
- Institutions own 16% of Chongqing Genrix Biopharmaceutical
If you want to know who really controls Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443), then you’ll have to look at the makeup of its share registry. With 55% stake, private equity firms possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
Following a 14% decrease in the stock price last week, private equity firms suffered the most losses, but institutions who own 16% stock also took a hit.
Let’s delve deeper into each type of owner of Chongqing Genrix Biopharmaceutical, beginning with the chart below.
See our latest analysis for Chongqing Genrix Biopharmaceutical

What Does The Institutional Ownership Tell Us About Chongqing Genrix Biopharmaceutical?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Chongqing Genrix Biopharmaceutical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can’t rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there’s always a risk that they are in a ‘crowded trade’. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Chongqing Genrix Biopharmaceutical’s historic earnings and revenue below, but keep in mind there’s always more to the story.

Hedge funds don’t have many shares in Chongqing Genrix Biopharmaceutical. Looking at our data, we can see that the largest shareholder is Chongqing Zhirui Investment Co., Ltd. with 55% of shares outstanding. This implies that they have majority interest control of the future of the company. Jikuan Shan is the second largest shareholder owning 4.0% of common stock, and Zhong Ou Fund Management Co., Ltd holds about 3.6% of the company stock.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock’s expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
Insider Ownership Of Chongqing Genrix Biopharmaceutical
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Shareholders would probably be interested to learn that insiders own shares in Chongqing Genrix Biopharmaceutical Co., Ltd.. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around CN¥671m worth of shares (at current prices). It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a 14% stake in Chongqing Genrix Biopharmaceutical. While this group can’t necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Equity Ownership
With a stake of 55%, private equity firms could influence the Chongqing Genrix Biopharmaceutical board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
Private Company Ownership
It seems that Private Companies own 8.5%, of the Chongqing Genrix Biopharmaceutical stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it’s hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Chongqing Genrix Biopharmaceutical is showing 3 warning signs in our investment analysis , and 1 of those makes us a bit uncomfortable…
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.